Gland Pharma FY26 profit jumps 50%, final dividend ₹20

Key update from FY26 results

Gland Pharma Limited reported a strong set of consolidated numbers for the financial year ended March 31, 2026, led by higher profitability and a sharp rise in adjusted profit after tax (PAT). The company said consolidated revenue grew 14.5% in FY26, while consolidated adjusted PAT rose 50% year-on-year. Alongside the results, the board recommended a final dividend of ₹20 per equity share (face value ₹1 each), subject to shareholder approval. The dividend decision comes with clear timelines for the record date and the company’s Annual General Meeting (AGM).

The announcement also carried detailed fourth-quarter performance, where both revenue and profits expanded sharply versus the year-ago period. Management commentary pointed to margin improvement and progress across businesses, including Cenexi, as a key contributor to the FY26 outcome.

FY26 headline numbers: revenue and adjusted PAT

For the full year FY26, Gland Pharma reported consolidated revenue of ₹6,430.7 crore, representing a 14% increase over the previous year. The company also stated consolidated revenue growth of 14.5% for FY26, indicating a similar year-on-year trend from different disclosures in the same update.

Consolidated adjusted PAT for FY26 came in at ₹1,045.5 crore, marking 50% year-on-year growth. The scale of the adjusted PAT increase compared with revenue growth indicates that the year’s improvement was driven more by profitability and cost or mix changes than by topline growth alone, as per the company’s own profitability commentary.

Q4 FY26 performance: sharp profit growth

For the fourth quarter ended March 31, 2026, the company posted revenue of ₹1,742.8 crore, up 22% compared to the same period in the previous year. Consolidated adjusted PAT for the quarter rose 97% year-on-year to ₹366.7 crore.

The company separately reported that consolidated net profit increased 96.62% to ₹366.7 crore on a 22.31% rise in net sales to ₹1,742.8 crore in Q4 FY26 over Q4 FY25. Profit before tax (PBT) stood at ₹505.79 crore in Q4 FY26, up 75.42% from ₹288.33 crore in Q4 FY25.

Profitability: EBITDA, margins, and what management highlighted

Gland Pharma reported consolidated EBITDA of ₹513 crore for the March 2026 quarter, up 48% year-on-year, with an EBITDA margin of 29%. For FY26, Executive Chairman Srinivas Sadu said the performance reflected consolidated revenue growth of 14.5% and an adjusted EBITDA margin of 26%.

He also stated that the base business delivered a 38% adjusted EBITDA margin, supported by robust growth in the CDMO segment, along with new product launches and improved profitability across the existing portfolio. Management attributed part of the improvement to ongoing cost-efficiency initiatives, and also referenced progress across businesses including Cenexi.

Geography and sales mix points disclosed for Q4

The company disclosed selected geography-wise sales for the quarter. Sales in Canada, Australia and New Zealand were ₹58.8 crore, down 2% year-on-year. Sales in India were ₹67 crore, up 28% year-on-year.

These figures provide a snapshot of how specific markets moved during the quarter, though the update did not provide a full region-wise breakdown for all geographies.

Dividend: amount, record date, AGM, and payout timeline

The board recommended a final dividend of ₹20 per equity share of face value ₹1 each (2000%) for FY26. The record date for determining eligible shareholders is Tuesday, August 11, 2026. The company’s 48th AGM is scheduled for Tuesday, August 25, 2026, and will be held via video conferencing.

If shareholders approve the proposal, the dividend will be paid within 30 days from the date of the 48th AGM. The company explicitly linked the payment timeline to AGM approval.

Market reaction: stock ends lower

Following the update, shares of Gland Pharma fell 1.80% to close at ₹1,861 on the BSE, as reported in the same information set.

Key numbers at a glance (₹ crore)

Dividend history context mentioned in the update

The information set also referenced a prior dividend declared at ₹18 per share, with an ex-date and record date of 14-Aug-2025, and a declaration date of 20-May-2025. It also listed an earlier final dividend of ₹20 per share with record date 16-Aug-2024.

What investors will watch next

One upcoming date mentioned is May 15, 2026, described as the upcoming earnings date for Gland Pharma Ltd. The same note also labels it as “Q4 FY26-27,” and no additional detail was provided alongside it.

The next confirmed corporate action on the FY26 dividend track is the record date on August 11, 2026, followed by the AGM on August 25, 2026. Shareholders will focus on AGM approval, since the final dividend payout timeline is explicitly tied to it.

Conclusion

Gland Pharma’s FY26 results showed mid-teens revenue growth alongside a much faster rise in adjusted PAT, with Q4 continuing that momentum through strong profit growth and a higher EBITDA margin. The board’s recommended ₹20 final dividend sets up an August 2026 timetable, with the record date on August 11 and the 48th AGM on August 25 via video conferencing. The next key step is shareholder approval, after which the company has said it will pay the dividend within 30 days of the AGM date.